0001183740-20-000111.txt : 20200527 0001183740-20-000111.hdr.sgml : 20200527 20200527151408 ACCESSION NUMBER: 0001183740-20-000111 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20200527 DATE AS OF CHANGE: 20200527 EFFECTIVENESS DATE: 20200527 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Algernon Pharmaceuticals Inc. CENTRAL INDEX KEY: 0001642178 IRS NUMBER: 000000000 STATE OF INCORPORATION: A1 FISCAL YEAR END: 0831 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-367771 FILM NUMBER: 20915019 BUSINESS ADDRESS: STREET 1: SUITE 915 - 700 WEST PENDER STREET CITY: VANCOUVER STATE: A1 ZIP: V6C 1G8 BUSINESS PHONE: 604-646-1553 MAIL ADDRESS: STREET 1: SUITE 915 - 700 WEST PENDER STREET CITY: VANCOUVER STATE: A1 ZIP: V6C 1G8 FORMER COMPANY: FORMER CONFORMED NAME: Breathtec BioMedical, Inc. DATE OF NAME CHANGE: 20161207 FORMER COMPANY: FORMER CONFORMED NAME: Breathtec Biomedical, Inc. DATE OF NAME CHANGE: 20150512 D 1 primary_doc.xml X0708 D LIVE 0001642178 Algernon Pharmaceuticals Inc. SUITE 915 - 700 WEST PENDER STREET VANCOUVER A1 BRITISH COLUMBIA, CANADA V6C 1G8 604-646-1553 BRITISH COLUMBIA, CANADA Breathtec BioMedical, Inc. Breathtec Biomedical, Inc. Corporation true 2015 Christopher Moreau Suite 915 - 700 West Pender Street Vancouver A1 BRITISH COLUMBIA, CANADA V6C 1G8 Executive Officer Michael Sadhra Suite 915 - 700 West Pender Street Vancouver A1 BRITISH COLUMBIA, CANADA V6C 1G8 Executive Officer Director Raj Attariwala Suite 915 - 700 West Pender Street Vancouver A1 BRITISH COLUMBIA, CANADA V6C 1G8 Director David Levine Suite 915 - 700 West Pender Street Vancouver A1 BRITISH COLUMBIA, CANADA V6C 1G8 Director Biotechnology Decline to Disclose 06b false 2020-05-13 true true true true true Each Special Warrant is convertible into a unit comprised of a share and one warrant for no additional consideration. Each warrant is exercisable into a share at C$0.55 per share for 24 months, subject to acceleration. false 0 128442 49949 78493 200835 Special Warrants at C$0.35(US$0.25) per Special Warrant, convertible into a share and a warrant, exercisable at C$0.55(US$0.39) for 24 months, subject to acceleration. No guarantee that Warrants will be exercised. Exchange rate of US$1:C$0.7106. false 1 0 0 0 false Algernon Pharmaceuticals Inc. /s/ Mike Sadhra Mike Sadhra CFO 2020-05-26